| 词条 | Vildagliptin/metformin |
| 释义 |
| drug_name = | type = combo | component1 = Vildagliptin | class1 = Dipeptidyl peptidase-4 inhibitor | component2 = Metformin | class2 = Biguanide antihyperglycemic agent | pronounce = | tradename = Eucreas, Galvumet | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_AU_comment = | legal_BR = | legal_BR_comment = | legal_CA = | legal_UK = | legal_US = | legal_UN = | legal_NZ = | legal_status = Rx-only | routes_of_administration = | CAS_number = | ATCvet = | ATC_prefix = | ATC_suffix = | PubChem = | DrugBank = }}Vildagliptin/metformin (trade names Eucreas and Galvumet) is a combination drug for the treatment of type 2 diabetes.[1] It was approved by the European Medicines Agency in 2008.[2] It combines 50 mg vildagliptin with either 500, 850, or 1000 mg metformin.[3] References1. ^{{Cite journal | pmc = 2515409| year = 2008| last1 = Halimi| first1 = S| title = Combination treatment in the management of type 2 diabetes: Focus on vildagliptin and metformin as a single tablet| journal = Vascular Health and Risk Management| volume = 4| issue = 3| pages = 481–492| last2 = Schweizer| first2 = A| last3 = Minic| first3 = B| last4 = Foley| first4 = J| last5 = Dejager| first5 = S}} {{pharma-stub}}2. ^{{Cite web | title = EU approves Novartis's Eucreas diabetes drug | url = https://www.reuters.com/article/companyNews/idUSZAT00747520080225 | publisher = Reuters | date = February 25, 2008}} 3. ^{{cite web | url = https://www.news-medical.net/drugs/Galvumet.aspx | title = Galvumet}} 2 : Combination drugs|Anti-diabetic drugs |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。